REFERENCES

  1. Arrieta AC, Lee A, Tran MT. Invasive mold infections in children: navigating troubled waters with a broken compass. Infect Dis Ther. 2023;12(6):1465-1485. doi:10.1007/s40121-023-00819-9
  2. Konsoula A, Tsioutis C, Markaki I, Papadakis M, Agouridis AP, Spernovasilis N. Lomentospora prolificans: an emerging opportunistic fungal pathogen. Microorganisms. 2022;10(7):1317. doi:10.3390/microorganisms10071317
  3. Bartlett AW, Cann MP, Yeoh DK, et al. Epidemiology of invasive fungal infections in immunocompromised children; an Australian national 10-year review. Pediatr Blood Cancer. 2019;66(4). doi:10.1002/pbc.27564
  4. Carlesse F, Amaral AC, Gonçalves SS, et al. Outbreak of Fusarium oxysporum infections in children with cancer: an experience with 7 episodes of catheter-related fungemia. Antimicrob Resist Infect Control. 2017;6:93. doi:10.1186/s13756-017-0247-3
  5. Lehrnbecher T, Fisher BT, Phillips B, et al. Clinical practice guideline for systemic antifungal prophylaxis in pediatric patients with cancer and hematopoietic stem-cell transplantation recipients. J Clin Oncol. 2020;38(27):3205-3216. doi:10.1200/JCO.20.00158
  6. Groll AH, Pana D, Lanternier F, et al. 8th European Conference on Infections in Leukaemia: 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-haematopoietic cell transplantation. Lancet Oncol. 2021;22(6):e254-e269. doi:10.1016/S1470-2045(20)30723-3
  7. Wattier RL, Dvorak CC, Hoffman JA, et al. A prospective, international cohort study of invasive mold infections in children. J Pediatric Infect Dis Soc. 2015;4(4):313–22. doi:10.1093/jpids/piu074
  8. Gwinn KD, Leung MCK, Stephens AB, Punja ZK. Fungal and mycotoxin contaminants in cannabis and hemp flowers: implications for consumer health and directions for further research. Front Microbiol. 2023;14:1278189. doi:10.3389/fmicb.2023.1278189
  9. Tragiannidis A, Roilides E, Walsh TJ, Groll AH. Invasive aspergillosis in children with acquired immunodeficiencies. Clin Infect Dis. 2012;54(2):258-267. doi:10.1093/cid/cir786
  10. Steinbach WJ. Epidemiology of invasive fungal infections in neonates and children. Clin Microbiol Infect. 2010;16(9):1321-1327. doi:10.1111/j.1469-0691.2010.03288.x
  11. Madney Y, Shalaby L, Hammad M, et al. COVID-19-associated pulmonary fungal infection among pediatric cancer patients, a single center experience. J Fungi (Basel). 2022;8(8):850. doi:10.3390/jof8080850
  12. Kanamori H, Rutala WA, Sickbert-Bennett EE, Weber DJ. Review of fungal outbreaks and infection prevention in healthcare settings during construction and renovation. Clin Infect Dis. 2015;61(3):433-444. doi:10.1093/cid/civ297
  13. Le TH, Kumar V, Gondal K, et al. Isolated central nervous system aspergillosis infection in a chronic lymphocytic leukemia patient on iIbrutinib: a case report. BMC Infect Dis. 2020;20(1):175. doi:10.1186/s12879-020-4894-2
  14. Justiz-Vaillant AA, Williams-Persad AF, Arozarena-Fundora R, et al. Chronic Granulomatous Disease (CGD): commonly associated pathogens, diagnosis and treatment. Microorganisms. 2023;11(9):2233. doi:10.3390/microorganisms11092233
  15. Vinh DC, Sugui JA, Hsu AP, Freeman AF, Holland SM. Invasive fungal disease in autosomal-dominant hyper-IgE syndrome. J Allergy Clin Immunol. 2010;125(6):1389-1390. doi:10.1016/j.jaci.2010.01.047
  16. Abbasi S, Shenep JL, Hughes WT, Flynn PM. Aspergillosis in children with cancer: A 34-year experience. Clin Infect Dis, 1999 Nov 01; 29(5):1210-1219. doi:10.1086/313445
  17. Walmsley S, Devi S, King S, et al. Invasive Aspergillus infections in a pediatric hospital: a ten-year review. Pediatr Infect Dis J. 1993 Aug;12(8):673-682. doi:10.1097/00006454-199308000-00009
  18. Burgos A, Zaoutis TE, Dvorak CC, et al. Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics. 2008;121(5):e1286-1294. doi:10.1542/peds.2007-2117
  19. van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004;39(10):1407-1416. doi:10.1086/422312
  20. Fisher BT, Zaoutis T, Dvorak CC, et al. Effect of caspofungin vs fluconazole prophylaxis on invasive fungal disease among children and young adults with acute myeloid leukemia: a randomized clinical trial. JAMA. 2019;322(17):1673-1681. doi:10.1001/jama.2019.15702
  21. Li L, Zhen X, Wang W. Clinical characteristics and prognoses of mucormycosis in four children. Infect Dis Ther, 2024;17:1971–1978. doi:10.2147/IDR.S462725
  22. Jariwal R, Heidari A, Sandhu A, et al. Granulomatous invasive Aspergillus flavus infection involving the nasal sinuses and brain. J Investig Med High Impact Case Rep. 2018;6:2324709618770473. doi:10.1177/2324709618770473
  23. Hill JA, Dalai SC, Hong DK, et al. Liquid biopsy for invasive mold infections in hematopoietic cell transplant recipients with pneumonia through next-generation sequencing of microbial cell-free DNA in plasma. Clin Infect Dis. 2021;73(11):e3876-e3883. doi:10.1093/cid/ciaa1639
  24. Rivelli Zea SM, Toyotome T. Azole-resistant Aspergillus fumigatus as an emerging worldwide pathogen. Microbiol Immunol. 2022;66(3):135-144. doi:10.1111/1348-0421.12957
  25. Ashouri N, Nieves D, Singh J, Arrieta A. 1342. Serial microbial cell-free DNA next generation sequencing (NGS) as a means of diagnosis and monitoring of clinical response to treatment of invasive fungal infections (IFI) in immunocompromised pediatric patients. Open Forum Infect Dis. 2022;9(2):ofac492. doi:10.1093/ofid/ofac492.1171
  26. Steinbach WJ. Latest thoughts on treating pediatric mucormycosis. J Pediatric Infect Dis Soc. 2020;9(5):640-644. doi:10.1093/jpids/piaa106. PMID: 33043976
  27. Clinicaltrials.gov. Posaconazole (MK-5592) intravenous and oral in children with invasive aspergillosis (IA) (MK-5592-104). NCT04218851. Accessed April 1, 2025. https://clinicaltrials.gov/study/NCT04218851?term=NCT04218851&rank=1
  28. Arrieta AC, Neely M, Day JC, et al. Safety, tolerability, and population pharmacokinetics of intravenous and oral isavuconazonium sulfate in pediatric patients. Antimicrob Agents Chemother. 2021;65(4):e00290-21. doi:10.1128/AAC.00290-21
  29. Segers H, Deville JG, Muller WJ, et al. Safety, outcomes, and pharmacokinetics of isavuconazole as a treatment for invasive fungal diseases in pediatric patients: a non-comparative phase 2 trial. Antimicrob Agents Chemother. 2024;68(12):e0048424. doi:10.1128/aac.00484-24
  30. Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387(10020):760-9. doi:10.1016/S0140-6736(15)01159-9
  31. Lewis JS 2nd, Wiederhold NP, Hakki M, Thompson GR 3rd. New perspectives on antimicrobial agents: isavuconazole. Antimicrob Agents Chemother. 2022;66(9):e0017722. doi:10.1128/aac.00177-22
  32. Nguyen MH, Davis MR, Wittenberg R, Mchardy I, Baddley JW, Young BY, Odermatt A, Thompson GR. Posaconazole drug levels associated with pseudohyperaldosteronism. Clin Infect Dis. 2020;70(12):2593-2598. doi: 10.1093/cid/ciz741
  33. McCreary EK, Davis MR, Narayanan N, et al. Utility of triazole antifungal therapeutic drug monitoring: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2023;43(10):1043-1050. doi:10.1002/phar.2850
  34. Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016 Aug 15;63(4):e1-e60. doi:10.1093/cid/ciw326
  35. Marty FM, Ostrosky-Zeichner L, Cornely OA, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16(7):828-837. doi:10.1016/S1473-3099(16)00071-2
  36. Ashkenazi-Hoffnung L, Bilavsky E, Levy I, et al. Isavuconazole as successful salvage therapy for mucormycosis in pediatric patients. Pediatr Infect Dis J. 2020;39(8):718-724. doi:10.1097/INF.0000000000002671
  37. Lanternier F, Poiree S, Elie C, et al. Prospective pilot study of high-dose (10 mg/kg/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis. J Antimicrob Chemother. 2015;70(11):3116-3123. doi:10.1093/jac/dkv236. PMID: 26316385
  38. John J, Loo A, Mazur S, Walsh TJ. Therapeutic drug monitoring of systemic antifungal agents: a pragmatic approach for adult and pediatric patients. Expert Opin Drug Metab Toxicol. 201;15(11):881-895. doi:10.1080/17425255.2019.1671971
  39. Friberg LE, Ravva P, Karlsson MO, Liu P. Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults. Antimicrob Agents Chemother. 2012;56(6):3032-3042. doi:10.1128/AAC.05761-11
  40. Bury D, Tissing WJE, Muilwijk EW, Wolfs TFW, Brüggemann RJ. Clinical pharmacokinetics of triazoles in pediatric patients. Clin Pharmacokinet. 2021;60(9):1103-1147. doi:10.1007/s40262-021-00994-3
  41. Neely M, Rushing T, Kovacs A, Jelliffe R, Hoffman J. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis. 2010;50(1):27-36. doi:10.1086/648679

TABLE OF CONTENTS

Faculty

George R. Thompson, III, MD

Professor of Medicine
University of California, Davis, School of Medicine
Sacramento, California

Antonio C. Arrieta, MD

Division Chief
Pediatric Infectious Diseases
Children’s Hospital of Orange County (CHOC)
Orange, California

MyCARE thanks Astellas for sponsoring this activity.

Copyright © 2025. ALL RIGHTS RESERVED. MyCARE Foundation. Astellas-sponsored, MA-MM-14973. May 2025. ASTELLAS and the Flying Star Logo are registered trademarks of Astellas Pharma Inc. Used with permission.